– USA, NC – Kincell Bio announced the appointment of Pete Buzy to its Board of Directors, as part of a $22 million round led by a new investor, NewSpring Capital.
About Pete Buzy
Pete Buzy is the former President and CEO of Catalent Cell & Gene Therapy, and brings over two decades of leadership in advanced biologics, having played a key role in building Catalent’s cell and gene therapy platform into one of the industry’s most advanced development and manufacturing organizations. Before that, he led one of NewSpring Healthcare’s portfolio companies, Paragon Bioservices, a contract development and manufacturing company focused on gene therapies. His appointment underscores Kincell Bio’s commitment to operational excellence and long-term growth.
“Kincell Bio is bringing the right focus, flexibility, and scientific rigor to a market that’s evolving rapidly,” said Pete Buzy. “I’m looking forward to supporting this team as they expand their capabilities for the next generation of cell therapy innovators. My history with NewSpring goes back more than a decade, including our work together at Paragon Bioservices, and I’ve seen firsthand how the right partnership can accelerate growth.”
About Kincell Bio
Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC, and Gainesville, FL, Kincell Bio is a contract development and manufacturing organization with the mission to streamline CMC development, apply expertise in analytical and process development,t and GMP manufacturing, testing, and release from early clinical to pivotal studies and product launch. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs, as well as developing expertise in stem cell products and iPSCs.
For more information: https://kincellbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.